Current Atherosclerosis Reports

, Volume 10, Issue 3, pp 227–229

Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE

  • Robert S. Rosenson
Clinical Trials Report
  • 17 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rosenson RS: Low high-density lipoprotein cholesterol and cardiovascular disease: risk reduction with statin therapy. Am Heart J 2006, 151:556–563.PubMedCrossRefGoogle Scholar
  2. 2.
    Barter P, Gotto AM, LaRosa JC, et al.: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007, 357:1301–1310.PubMedCrossRefGoogle Scholar
  3. 3.
    Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505–1515.PubMedCrossRefGoogle Scholar
  4. 4.
    Davidson MH, McKenney JM, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels. J Am Coll Cardiol 2006, 48:1774–1781.PubMedCrossRefGoogle Scholar
  5. 5.
    McKenney JM, Davidson MH, Shear CL, Revkin JH: Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin. J Am Coll Cardiol 2006, 48:1782–1790.PubMedCrossRefGoogle Scholar
  6. 6.
    Pfizer Inc.: In interests of patients safety, Pfizer stops all torcetrapib clinical trials; company has notified FDA and is in the process of notifying all clinical investigators and other regulatory authorities. Pfizer news release. December 2, 2006. Available at http://www.fda.gov/bbs/topics/NREWS/2006/NEW0154.html. Accessed October 30, 2007.
  7. 7.
    Barter PJ, Caulfield M, Eriksson M, et al.: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007, 357:2109–2122.PubMedCrossRefGoogle Scholar
  8. 8.
    Blood Pressure Lowering Trialists’ Collaboration: Effects of different blood pressure lowering regimens on major cardiovascular events: results of prospectively designed overviews of randomised trials. Lancet 2003, 362:1527–1535.CrossRefGoogle Scholar
  9. 9.
    Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.PubMedCrossRefGoogle Scholar
  10. 10.
    Forrest MJ, Sparrow CP: Torcetrapib-induced blood pressure elevation is independent of cholesteryl ester transfer protein inhibition and is accompanied by an increase in circulating aldosterone levels. Paper presented at American Heart Association Scientific Sessions. Orlando, FL; November 4–7, 2007.Google Scholar
  11. 11.
    Keidar S, Kaplan M, Pavlotzky E, et al.: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation 2004, 109:2213–2220.PubMedCrossRefGoogle Scholar
  12. 12.
    Rajagopalan S, Duquaine D, King S, et al.: Mineralcorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002, 105:2212–2221.PubMedCrossRefGoogle Scholar
  13. 13.
    Takai S, Jin D, Muramatsu M, et al.: Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 2005, 46:1135–1139.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Robert S. Rosenson

There are no affiliations available

Personalised recommendations